Impact du génotype de l'ACTN3 sur la conservation et l'évolution de la force musculaire chez les individus atteints de dystrophie myotonique de type 1

Authors: Allard-Chamard, Xavier
Advisor: Leone, Mario
Abstract: The purpose of this investigation was to analyze the impact of the genotype of ACTN3 on the conservation and evolution of muscle strength in individuals with DM1. This study was a longitudinal study, the patients having been evaluated on two different occasions with 9 years in between (time 1 and time 2). The analysis of the impact of the ACTN3 genotype had two components. The first part aimed at identifying whether the absence of alpha-actinin 3 protein (genotype 577XX) caused a lower level of overall muscular strength in people with DM1 when compared to the other two genotypes, in this case 577RX and 577RR. The second part aimed at comparing the loss of muscle strength between time 1 and time 2 for the three genotypes. Patients were recruited from the Saguenay Neuromuscular Clinic Registry. Those invited to participate in this study had been previously tested by a genetic analysis confirming the presence of the disease (adult and late phenotype) and be 18 years of age or older. A total of 113 participants, 42 men and 71 women, were able to complete this longitudinal study. These were assessed using 17 muscle tests. At time 2, results showed that the absence of alpha-actinin 3 protein in men with DM1 induced a lower level of overall muscle strength than men with 577RX genotype. Indeed, the male genotype 577XX had a more rapid decrease in strength over the years. In light of these results, knowing the genotype profile associated with the ACTN3 gene in men with DM1 is an important element to consider in order to optimize rehabilitation strategies.
Document Type: Mémoire de maîtrise
Issue Date: 2018
Open Access Date: 12 February 2019
Grantor: Université Laval
Collection:Thèses et mémoires

Files in this item:
34985.pdf3.94 MBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.